BMRN BIOMARIN PHARMACEUTICAL INC
Price Chart
Executive Summary
BioMarin filed an 8-K reporting results from its 2026 Annual Meeting of Stockholders. Shareholders approved all four proposals, including the election of ten director nominees, ratification of KPMG as auditor, an advisory vote on executive compensation, and an amendment to the 2017 Equity Incentive Plan to increase the share reserve by 7,650,000 shares. This is a routine administrative filing with no material financial impact.
Actionable Insight
Routine annual meeting results with no earnings or guidance implications. The equity plan amendment adds modest potential dilution (~4% of shares outstanding) but is standard practice. No trading action warranted.
Key Facts
- Shareholders approved an amendment to the 2017 Equity Incentive Plan, increasing the share reserve by 7,650,000 shares.
- All ten director nominees were elected with strong majority support.
- KPMG LLP was ratified as independent auditor for fiscal year 2026.
- Advisory vote on named executive officer compensation passed with ~87% of votes cast in favor.
- 193,270,028 shares were entitled to vote; 175,813,292 shares were present or represented at the meeting.
Financial Impact
No financial figures reported; equity plan amendment adds 7,650,000 shares to the reserve, representing approximately 3.96% of outstanding shares based on 193,270,028 shares entitled to vote.
Risk Factors
- Potential future dilution from equity awards granted under the amended plan.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-040812 |
| Document: 0001628280-26-040812-index-headers.html | 0001628280-26-040812 |
| Document: 0001628280-26-040812-index.html | 0001628280-26-040812 |
| Document: 0001628280-26-040812.txt | 0001628280-26-040812 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
10d ago
|
8-K
| $56.09 awaiting T+20 | awaiting T+20 | — | $55.95 (−0.25%) |
|
Apr 27, 2026
6w ago
|
8-K
| $53.62 $52.88 | ▼ −1.39% | ▼ −6.34% | $55.95 (+4.34%) |
|
Apr 21, 2026
7w ago
|
DEFA14A
| $54.16 $49.81 | ▼ −8.04% | ▼ −11.20% | $55.95 (+3.30%) |
|
Feb 28, 2026
15w ago
|
Institutional Cluster
| $59.71 $54.60 | ▼ −8.56% | ▼ −0.62% | $55.95 (−6.30%) |
|
Feb 26, 2026
15w ago
|
Insider Cluster
| $60.90 $55.32 | ▼ −9.16% | ▼ −2.76% | $55.95 (−8.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access